Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2024, titled "Zydus receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials".
Press Release Mar 14 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, which is used to treat various mental and mood disorders. The drug will be manufactured at the company's facility in Jarod, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 13 2024
- Press Release Feb 26 2024
- Press Release Feb 16 2024
- Press Release Feb 09 2024
- Press Release Feb 08 2024
Later from Zydus Lifesciences
- Press Release Mar 16 2024
- Press Release Mar 23 2024
- Press Release Apr 01 2024
- Press Release Apr 20 2024
- Zydus Lifesciences Limited Press Release Apr 22 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences